UKITP Registry

Trial overview

UK Adult Idiopathic Thrombocytopenic Purpura Registry

Inclusion criteria

Adult patients presenting at haematology clinics at The Royal London Hospital or collaborating centres with a low platelet count (< 150 × 109/L) and no evidence of known thrombocytopenic-inducing disease or treatments following a standard ITP workup will be invited to take part in the study.

Contact details

Chief Investigator

Dr Quentin Hill

Tel 0113 2068481

Email quentin.hill@leedsth.nhs.uk

Research Nurse

Alex Stichler

Tel 0113 2068577

Email alex.stichler@leedsth.nhs.uk



Other trials currently active for Thrombocytopenia

Symphogen 001-03

A multi-centre, single intravenous dose, exploratory dose-finding, open label trial on the safety and efficacy of Sym001 in the treatment of Immune Thrombocytopenic Purpura (ITP) in RhD positive, nonsplenectomized adult subjects.

Amgen Romiplostim ITP

A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receving Romiplostim.

 
The primary objective is to describe the number of months with a subject platelet response over a 12 month treatment period.
 

The secondary objectives are:

  1. To describe the incidence of ITP remission.
  2. To describe the incidence of splenectomy. 
  3. To describe the incidence of adverse events.


Tags

thrombocytopenia itp